Tenaya Therapeutics, Inc. (TNYA) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Tenaya Therapeutics, Inc. on January 28, 2025, reporting events occurring on January 24, 2025. The filing addresses Item 5.02 regarding the repricing of designated underwater stock options approved by the Compensation Committee.
Key Financial Metrics
The filing does not provide standard financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial data disclosed relates to the stock option repricing:
- Stock Price on Effective Date: $1.21 per share (closing price on January 24, 2025).
- Total Shares Underlying Repriced Options: Approximately 4,133,517 shares.
- Original Exercise Price Range: $3.06 to $21.01 per share.
- New Exercise Price: $1.21 per share.
Material Changes
The primary material change is the reduction of exercise prices for eligible nonstatutory stock options held by employees and service providers. Options with original exercise prices of $3.00 or higher were repriced to $1.21. This action was taken because a substantial majority of employee options were "underwater" (exercise price above market price). There was no change to expiration dates, vesting criteria, or the number of shares underlying the options.
Guidance, Outlook, and Management Commentary
Management stated the repricing was designed to retain and motivate employees without incurring significant stock dilution from new grants or additional cash expenditures. The Compensation Committee consulted an independent compensation consultant before approval.
Retention Conditions: To benefit from the lower exercise price, holders must meet a "Retention Goal Achievement" by remaining a service provider through July 24, 2025, or until a Change in Control occurs prior to that date. If an option is exercised before this goal is met, the holder must pay the original, higher exercise price.
Investor Verification Checklist
- Verify the total number of shares subject to repricing (approx. 4.13 million) against the company's total authorized share count to assess dilution impact.
- Confirm the specific number of options held by key executives, such as Chief Medical Officer Whit Tingley (630,982 shares), and their original exercise prices.
- Review the company's cash position and runway, as the filing notes the goal was to avoid significant cash expenditures for compensation.
- Monitor the stock price relative to the new $1.21 exercise price to determine if the options remain in-the-money.